Results 201 to 210 of about 209,459 (341)

Real World Study on the Best CPX‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (allo‐HSCT), and the activity of CPX‐351 in specific s‐AML subgroups are unclear.
Fabio Guolo   +56 more
wiley   +1 more source

An In Vitro Model for Hemostasis Monitoring During Simulated Cardiopulmonary Bypass [PDF]

open access: bronze, 1998
Daniel J. Beck   +6 more
openalex   +1 more source

Hereditary Spherocytosis due to an SPTA1 Nonsense Mutation Coinherited With α spectrinLELY in Trans

open access: yes
American Journal of Hematology, EarlyView.
María‐Angustias Molina‐Arrebola   +1 more
wiley   +1 more source

Risk Factors for and Impact of Pre‐Engraftment Syndrome on Outcomes Following Single‐Unit Cord Blood Transplantation in Adults

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pre‐engraftment syndrome (PES) is a unique complication of cord blood transplantation (CBT) whose risk factors and impact on transplant outcomes remain controversial. Using a nationwide database in Japan, we analyzed a total of 3734 patients who underwent single‐unit CBT.
Masatoshi Sakurai   +27 more
wiley   +1 more source

MDS/MPN With SF3B1 Mutation and Thrombocytosis but Without Ring Sideroblasts

open access: yes
American Journal of Hematology, EarlyView.
Biswadip Hazarika, Barbara J. Bain
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual‐Center Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Survival outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have improved with modern frontline therapies and minimal residual disease (MRD)‐guided strategies. As a result, allogeneic hematopoietic cell transplantation (HCT) is increasingly deferred in first remission (CR1) and used in the relapsed setting.
Oren Pasvolsky   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy